Long-term effects of isradipine on blood pressure and renal function

1989 ◽  
Vol 86 (4) ◽  
pp. 15-18 ◽  
Author(s):  
Ole Lederballe Pedersen ◽  
Lars R. Krusell ◽  
Inger Sihm ◽  
Lennard Tang Jespersen ◽  
Klaus Thomsen
PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e88269 ◽  
Author(s):  
Jie Yan ◽  
Xin Li ◽  
Rina Su ◽  
Kai Zhang ◽  
Huixia Yang

1988 ◽  
Vol 6 (11) ◽  
pp. 1728-1731 ◽  
Author(s):  
S W Hansen ◽  
S Groth ◽  
G Daugaard ◽  
N Rossing ◽  
M Rørth

Long-term effects of cisplatin on renal function were investigated in 34 patients with germ cell cancer observed for a median of 65 months (range, 43 to 97 months). All patients achieved a complete remission after treatment with cisplatin (median dose 583 mg/m2), vinblastine, and bleomycin. None of the patients relapsed during follow-up. During treatment the glomerular filtration rate (GFR) decreased by 18% (P less than .05). During follow-up kidney function recovered in ten patients and partly improved in eight patients. Changes in plasma creatinine did not consistently correspond to alterations in GFR. The mean increase in systolic blood pressure during follow-up did not differ from the increase seen in a group of age-matched healthy men. The mean increase in diastolic pressure, however, was significant (P less than .05), but was entirely due to hypertension observed in six patients. Renography of these patients was normal. We conclude that the decrease in GFR observed during treatment with cisplatin is partly reversible. Cisplatin-treated patients have an increased risk of developing hypertension years after treatment.


2011 ◽  
Vol 6 (6) ◽  
pp. 1474-1480 ◽  
Author(s):  
Milos N. Budisavljevic ◽  
Paul J. Nietert ◽  
Yusheng Zhai ◽  
Mary J. Dooley ◽  
P.R. Rajagopalan

2008 ◽  
Vol 179 (3) ◽  
pp. 964-969 ◽  
Author(s):  
Waleed A. Eassa ◽  
Khaled Z. Sheir ◽  
Hossam M. Gad ◽  
Mohamed E. Dawaba ◽  
Mahmoud R. El-Kenawy ◽  
...  

Drug Research ◽  
2017 ◽  
Vol 67 (11) ◽  
pp. 640-646 ◽  
Author(s):  
Takeyuki Hiramatsu ◽  
Akiko Ozeki ◽  
Hideaki Ishikawa ◽  
Shinji Furuta

Abstract Aims Very few studies have ever examined the effects of long-term (>1 year) administration of liraglutide in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Therefore, we conducted a 2-year study to prospectively examine the effects of liraglutide in those patients. Methods A total of 148 patients with T2DM were enrolled and treated with liraglutide (0.6 or 0.9 mg/day). 97 patients completed the 2-year study without protocol deviations. These patients were divided into 3 groups according to the baseline estimated glomerular filtration ratio (eGFR) (in mL/min/1.73 m2): group A, ≥60 (n=39); group B, ≥30 to <60 (n=38); and group C, <30 (n=20). The changes in blood and urine variables, and echocardiographic left ventricular mass index (LVMI) from baseline to 2 years were analyzed in each group. Primary outcomes were changes of the renal parameters of eGFR and albuminuria after the treatment of liraglutide. Results Blood glucose and systolic blood pressure decreased significantly after 24 months of liraglutide treatment in all groups compared with baseline (p<0.05). The eGFR increased significantly in group B (p<0.05), and remained unchanged in groups A and C. Albuminuria and LVMI decreased significantly in all 3 groups compared with baseline (p<0.05). Conclusions These findings suggest that 2 years of liraglutide treatment in Japanese patients with T2DM and impaired renal function was effective in terms of suppressing the deterioration of renal function, and reducing albuminuria. Long-term liraglutide treatment also improved glycemic control and blood pressure, and reduced left ventricular hypertrophy in this study.


2004 ◽  
Vol 93 (1) ◽  
pp. c35-c46 ◽  
Author(s):  
Jan R. Köhler ◽  
Jan Tencer ◽  
Hans Thysell ◽  
Lillemor Forsberg ◽  
Mikael Hellström

2003 ◽  
Vol 179 (2) ◽  
pp. 275-280 ◽  
Author(s):  
M Dodic ◽  
M Tersteeg ◽  
A Jefferies ◽  
EM Wintour ◽  
K Moritz

Low-dose dexamethasone treatment is used in pregnancies where the fetus is suspected to be at risk of congenital adrenal hyperplasia (CAH). In order to see if such treatment had long-term effects, pregnant ewes were treated with dexamethasone (20 micro g/kg maternal body weight) or saline from 25 to 45 days of gestation and blood pressure and renal function studied in offspring at 2 Years of age. There were 11 animals from dexamethasone treatment (six females and five males) and nine lambs from saline treatment (five females and four males). We aimed to study blood pressure and heart rate in the adult animals of both genders, and renal function only in the adult female animals.In both females and males, blood pressure and heart rate were similar between the two groups of animals. The excretion rates of sodium and potassium were similar between the two groups of animals. In addition, glomerular filtration rate was not different between the two groups of animals (112+/-11 ml/kg per h (S.E.M.) in saline-treated females vs 112+/-10 ml/kg per h in dexamethasone-treated females). There were no differences in body weight or weights of the kidney and heart between the treatments in both females and males.In conclusion, these results are reassuring for patients similarly exposed to prenatal dexamethasone treatment for CAH, as in our animal model no evidence of altered renal function or predisposition to adult hypertension was found.


Sign in / Sign up

Export Citation Format

Share Document